Research programme: controlled-release pain therapeutics - Flamel Technologies

Drug Profile

Research programme: controlled-release pain therapeutics - Flamel Technologies

Alternative Names: Trigger Lock therapeutics - Flamel Technologies

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Flamel Technologies
  • Developer Avadel Pharmaceuticals
  • Class Opioid analgesics
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 04 Jun 2013 Controlled-release pain therapeutics programme is available for licensing as of 04 Jun 2013. http://www.flamel.com/
  • 17 Oct 2011 Preclinical development is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top